24 Nov 2020
Posted in Pharma
Diagnosed prevalent cases of acromegaly in the US is projected to increase by 11.8% over the next decade
The diagnosed prevalent cases of acromegaly in the seven major markets (7MM*) combined is projected to increase from 43,220 cases in 2019 to 47,340 in 2029, at an annual growth rate (AGR) of 0.95%, according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Acromegaly and Gigantism – Epidemiology Forecast to 2029’, notes that the major drivers for the upward trend in the diagnosed prevalent cases of acromegaly may be attributable to better awareness of the disease, as well as improved diagnostic techniques and changing population demographics in the respective markets.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “The majority of the diagnosed prevalent cases of acromegaly in the 7MM are expected to occur in men and women ages 40–69 years, which, in this analysis, is driven by a higher proportion of the population being in this age group. Acromegaly is more common in women, who present at an older age with longer diagnostic delay. At presentation, women have a higher growth hormone level than men. Among acromegaly patients, quality of life is more adversely affected in women both before and after treatment.”
Among the 7MM, the US is expected to have the highest number of diagnosed prevalent cases of acromegaly with 26,549 cases in 2019 and increasing at an AGR of 1.18% (2019¬–2029), followed by Italy (4,005 cases) and Germany (3,354 cases).
*7MM: US, France, Germany, Italy, Spain, UK, and Canada